Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

NCT01376713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Stage III Melanoma
Stage IV Melanoma

Interventions

BIOLOGICAL: Ofatumumab
BIOLOGICAL: Ofatumumab plus Dacarbazine

Sponsor

Medical University of Vienna